Camlin Fine Sciences Ltd — earnings calls

Camlin Fine Sciences reported Q1 FY27 revenue of INR5,199 million, up around 28% year-on-year, but EBITDA margins fell sharply due to elevated raw material, freight and financing costs. Management said the diphenol plant remained shut for economic reasons while ethyl vanillin ramp-up was slower than planned, resulting in negative EBITDA in the Aroma segment. The company revised its full-year revenue and margin guidance downward, citing the prolonged geopolitical conflict and its impact on raw material prices and working capital.

Camlin Fine Sciences reported Q4 revenue of INR424 crores and full-year revenue of INR1,723 crores, with management attributing part of the shortfall to shipping delays and freight disruption linked to a geopolitical conflict. Quarterly EBITDA came in at INR21 crores, or about 5% margin, which management linked to higher freight costs, the Vinpai acquisition's liquidity-related losses, and a switch from methyl to ethyl vanillin production. Management also described the liquidation of CFS Europe, a resulting accounting gain of roughly INR100 crores, and a recent fire incident at the Dahej plant that led to a decision to import hydroquinone rather than continue diphenol manufacturing.